Opioid abuse, drug compounding and drug shortages are some of the key issues FDA’s drug center will focus on in 2020, drug center director Janet Woodcock said in an email Monday (Jan. 13). In the email, which contained few details about the agency’s future plans in each area, Woodcock laid out how FDA has already taken action on myriad issues, including postmarket safety initiatives and regulatory reform for new drugs, and she said the agency will continue that work throughout...